Literature DB >> 28296711

Prognostic role of the histological subtype of melanoma on the hands and feet in Caucasians.

Cristina Carrera1, Adrià Gual, Alba Díaz, Joan A Puig-Butillé, Susanna Noguès, Antonio Vilalta, Carlos Conill, Ramón Rull, Ramon Vilana, Pedro Arguis, Sergi Vidal-Sicart, Llucia Alós, Josep Palou, Teresa Castel, Josep Malvehy, Susana Puig.   

Abstract

Acral melanoma (AM) is associated with a poor prognosis in part because of delayed diagnosis, but probably also because of other intrinsic characteristics of location. The aim of this study was to review the specific characteristics and outcome of AM in Caucasians. This was a cross-sectional retrospective clinical-pathological study of 274 patients identified with AM in the database of a referral unit in Europe from 1986 to 2010. The mean age of the patients was 56.6 (SD 17.7) years. 269 cases could be histologically classified and included in the study. In all, 222 (82.5%) were located on feet. According to melanoma subtype, 165 (61.3%) were acral lentiginous melanoma (ALM), 84 (31.2%) were superficial spreading melanoma (SSM), and 20 (7.5%) were nodular melanoma (NM). SSM patients were characterized by female predominance (77.4%), younger age, and classic melanoma-risk phenotype (fair skin and multiple nevi). Among the 198 invasive cases with a mean follow-up of 56.2 months, the mean (SD) Breslow's thickness was 3.1 (3.6) mm, being 1.4 (1.4) mm in SSM, 3.5 (4.1) mm in ALM and 4.9 (2.9) mm in NM (P<0.001). Ulceration was present in 33.3%, 2.9% in SSM, 38.6% in ALM, and 76.9% in NM (P<0.001). A total of 29.3% relapsed (7.3% of SSM, 35% of ALM and 55% of NM) and 24.2% died because of AM. In multivariate analysis, age at diagnosis, Breslow, and histopathological subtype were independent prognostic factors for both disease-free and AM-specific survival. The ALM and NM subtypes presented poorer outcome after weighting Breslow and age (P=0.02). Histological subtype of AM could have an impact on biological behavior, ALM and NM subtypes presenting a poorer prognosis after adjusting for age and Breslow's thickness.

Entities:  

Mesh:

Year:  2017        PMID: 28296711     DOI: 10.1097/CMR.0000000000000340

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  10 in total

1.  Clinical and genetic analysis of melanomas arising in acral sites.

Authors:  Anne Zaremba; Rajmohan Murali; Philipp Jansen; Inga Möller; Antje Sucker; Annette Paschen; Lisa Zimmer; Elisabeth Livingstone; Titus J Brinker; Eva Hadaschik; Cindy Franklin; Alexander Roesch; Selma Ugurel; Dirk Schadendorf; Klaus G Griewank; Ioana Cosgarea
Journal:  Eur J Cancer       Date:  2019-08-14       Impact factor: 9.162

2.  Interdigital Melanoma of the Foot Affecting Two Neighbouring Interdigital Spaces - Second Case Report.

Authors:  Uwe Wollina; Carsten Rilke; Gesina Hansel; Dana Langer; Jacqueline Schönlebe; Georgi Tchernev
Journal:  Open Access Maced J Med Sci       Date:  2017-07-19

3.  Subtyping Cutaneous Melanoma Matters.

Authors:  Mary-Ann El Sharouni; Paul Johannes van Diest; Arjen Joost Witkamp; Vigfús Sigurdsson; Carla Henrica van Gils
Journal:  JNCI Cancer Spectr       Date:  2020-10-23

4.  Germline variants are associated with increased primary melanoma tumor thickness at diagnosis.

Authors:  Ernest Mangantig; Stuart MacGregor; Mark M Iles; Richard A Scolyer; Anne E Cust; Nicholas K Hayward; Grant W Montgomery; David L Duffy; John F Thompson; Anjali Henders; Lisa Bowdler; Casey Rowe; Gemma Cadby; Graham J Mann; David C Whiteman; Georgina V Long; Sarah V Ward; Kiarash Khosrotehrani; Jennifer H Barrett; Matthew H Law
Journal:  Hum Mol Genet       Date:  2021-01-06       Impact factor: 6.150

5.  Prognostic factors and population-based analysis of melanoma with sentinel lymph node biopsy.

Authors:  Ping-Chung Wu; Yu-Ching Chen; Hsiu-Min Chen; Lee-Wei Chen
Journal:  Sci Rep       Date:  2021-10-15       Impact factor: 4.379

6.  Acral Lentiginous Melanoma: A United States Multi-Center Substage Survival Analysis.

Authors:  Avani M Kolla; Gerardo A Vitiello; Erica B Friedman; James Sun; Aishwarya Potdar; Hala Daou; Norma E Farrow; Clara R Farley; John T Vetto; Dale Han; Marvi Tariq; Georgia M Beasley; Carlo M Contreras; Michael Lowe; Jonathan S Zager; Iman Osman; Russell S Berman; Tracey N Liebman; Jennifer A Stein; Ann Y Lee
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

7.  Does acral melanoma need a distinctive prognostic staging system?

Authors:  Cristina Carrera; Sebastian Podlipnik
Journal:  Br J Dermatol       Date:  2022-05-03       Impact factor: 11.113

8.  Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma.

Authors:  Paul Johannet; Nicolas Coudray; Douglas M Donnelly; George Jour; Irineu Illa-Bochaca; Yuhe Xia; Douglas B Johnson; Lee Wheless; James R Patrinely; Sofia Nomikou; David L Rimm; Anna C Pavlick; Jeffrey S Weber; Judy Zhong; Aristotelis Tsirigos; Iman Osman
Journal:  Clin Cancer Res       Date:  2020-11-18       Impact factor: 13.801

9.  Web-based nomograms for predicting the prognosis of adolescent and young adult skin melanoma, a large population-based real-world analysis.

Authors:  Chen Yang; Fei Liao; Li Cao
Journal:  Transl Cancer Res       Date:  2020-11       Impact factor: 1.241

10.  Risk factors of recurrence and distant metastasis in primary cutaneous melanoma in Taiwan.

Authors:  Tung-Lin Lee; Yi-Hua Liao; Jau-Yu Liau; Yi-Shuan Sheen
Journal:  Sci Rep       Date:  2021-10-25       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.